Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.18 +0.30 (+0.64%)
Official Closing Price Updated: 7:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Price Over Earnings Overview: Bristol-Myers Squibb
 
Via Benzinga
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
1 Profitable Stock Worth Investigating and 2 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability and Growth Prospects
Bristol-Myers Squibb (BMY) is a top dividend stock with a 5.12% yield, strong profitability, and a solid financial health rating, making it a compelling choice for income investors. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'
Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and Live Nation also highlighted. 
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Identified as a Top Value Stock with Strong Fundamentals
Bristol-Myers Squibb (BMY) is a top value stock with a low P/E ratio of 7.2, strong profitability, and a high 5.19% dividend yield. 
Via Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
How Do Investors Really Feel About Bristol-Myers Squibb?
 
Via Benzinga
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
The dividend stocks listed below all yield more than 5% and look like safe long-term buys. 
Via The Motley Fool
BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
PRME Revenue Misses by 73%
Via The Motley Fool
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point. 
Via The Motley Fool
Topics Economy
Why Is Replimune Stock Trading Lower On Monday?
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial. 
Via Benzinga
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Bristol Myers (BMY) Q2 EPS Jumps 36%
Via The Motley Fool
Topics Intellectual Property
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Bristol-Myers Squibb Unusual Options Activity For July 31
 
Via Benzinga
Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results... 
Via StockStory
Topics Intellectual Property World Trade
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.